Prevalence of hepatitis B virus infection in the Netherlands in 1996 and 2007

Epidemiology and Infection

Volumn 140, Issue 8, 2012, Pages 1469-1480

  Hahne S J M ^a   De Melker, H E ^a   Kretzschmar, M ^a,b   Mollema, L ^a   Van Der Klis, F R ^a   Van Der Sande, M A B ^a,b   Boot, H J ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anti HBc; HBsAg; HBV DNA; hepatitis B; prevalence; The Netherlands

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ASIAN; BLOOD TRANSFUSION; CHILD; ENDEMIC DISEASE; FEMALE; HEPATITIS B; HUMAN; IMMIGRANT; INDIGENOUS PEOPLE; INFANT; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DATA COLLECTION; EMIGRATION AND IMMIGRATION; HEPATITIS B, CHRONIC; HUMANS; INFANT; MIDDLE AGED; NETHERLANDS; PREVALENCE; QUESTIONNAIRES; TIME FACTORS; TRAVEL; YOUNG ADULT;

EID: 84863928244     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S095026881100224X     Document Type: Article

References (25)

1. Mast E, Ward J. Hepatitis B vaccines. In: Vaccine. 5th edn. Philadelphia : Saunders Elsevier, 2008.
2. Shepard CW, et al. Hepatitis B virus infection : epidemiology and vaccination. Epidemiologic Reviews 2006; 28: 112-125.
3. Medley GF, et al. Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control. Nature Medicine 2001; 7: 619-624
4. Grosheide PM, Klokman-Houweling JM, Conyn-van Spaendonck MA. Programme for preventing perinatal hepatitis B infection through screening of pregnant women and immunisation of infants of infected mothers in The Netherlands, 1989-92. National Hepatitis B Steering Committee. British Medical Journal 1995; 311: 1200-1202.
5. Health Council of The Netherlands. General vaccination against hepatitis B revisited. The Hague: Health Council of the Netherlands; 2009. Report No.: 2008/03E.
6. Ministry of Health and Welfare. Infants to be vaccinated against hepatitis B. Internet communication, 22 July 2010 ( 07/22/baby-s-ook-ingeent- tegen-hepatitis-b.html) [in Dutch]. Accessed 21 March 2011.
7. Hahné S, Wormann Nee MT, Kretzschmar M. Migrants and hepatitis B: new strategies for secondary prevention needed. European Journal of Public Health 2009; 19: 439.
8. de Melker HE, Conyn-van Spaendonck MA. Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiology and Infection 1998; 121: 637-643.
9. van der Klis FR, et al. Second national serum bank for population-based seroprevalence studies in the Netherlands. Netherlands Journal of Medicine 2009; 67: 301-308.
10. Boot HJ, et al. Improved tracing of hepatitis B virus transmission chains by phylogenetic analysis based on C region sequences. Journal of Medical Virology 2008; 80: 233-241.
11. Boot HJ, et al. Persistent and transient hepatitis B virus (HBV) infections in children born to HBV-infected mothers despite active and passive vaccination. Journal of Viral Hepatitis 2010; 17: 872-878.
12. Oehlert G. A note on the delta method. American Statistician 1992; 46: 27-29.
13. Deubner DC, et al. Logistic model estimation of death attributable to risk factors for cardiovascular disease in Evans County, Georgia. American Journal of Epidemiology 1980; 112: 135-143.
14. Rao JNK, Wu CFJ, Yue K. Some recent work on resampling methods for complex surveys. Survey Methodology 1992; 18: 209-217.
15. Nardone A, et al. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiology and Infection 2009; 137: 961-969.
16. Veldhuijzen IK, Hahné SJM. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. ECDC 2010. Report No.: ISBN 978- 92-9193-213-9.
17. Merrill RM, Hunter BD. Seroprevalence of markers for hepatitis B viral infection. International Journal of Infectious Diseases 2011; 15: e78-121.
18. Baaten GG, et al. Population-based study on the seroprevalence of hepatitis A, B, and C virus infection in Amsterdam, 2004. Journal of Medical Virology 2007; 79: 1802-1810.
19. Health Council of the Netherlands. Universal vaccination against hepatitis B. 2001. Report No.: 2001/03.
20. van Ballegooijen WM, et al. Molecular sequence data of hepatitis B virus and genetic diversity after vaccination. American Journal of Epidemiology 2009; 170: 1455-1463.
21. Hahné SJ, et al. Hepatitis B virus transmission in The Netherlands: a population-based, hierarchical case-control study in a very low-incidence country. Epidemiology and Infection 2007; 136: 184-195.
22. Edmunds WJ, et al. The influence of age on the development of the hepatitis B carrier state. Proceedings of the Royal Society of London, Series B: Biological Sciences 1993; 253: 197-201.
23. Marschall T, et al. High impact of migration on the prevalence of chronic hepatitis B in the Netherlands. European Journal of Gastroenterology and Hepatology 2008; 20: 1214-1225.
24. Schmidt M, et al. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sanguinis 2006; 91: 237-243.
25. Veldhuijzen IK, et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is costeffective. Gastroenterology 2009: 138: 522-530.